UndisclosedDivestiture / carve-outHealthcare & Life SciencesCompleted
AmyriAD buys AD04 Alzheimer's program from ADvantage
Amsterdam-based AmyriAD Therapeutics acquired the AD04 program, which targets neuroinflammation in mild Alzheimer's disease, and related assets from ADvantage Therapeutics. Terms were not disclosed.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →